Evidence map›Paper›PMID 41610080›Full record

Trial reportOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde2026

Patient-Reported Outcomes after Surgery for Proliferative Vitreoretinopathy: Post hoc Analysis of a Randomized Controlled Trial.

Rodrigo Anguita, Lorenzo Ferro Desideri, Janice Roth, Ines Schumacher, Philip Banerjee, Martin Zinkernagel, David G Charteris

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rodrigo AnguitaMoorfields Eye Hospital NHS Foundation Trust, London, UK, rodrigoanguita@gmail.com.
Lorenzo Ferro DesideriDepartment of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland.
Janice RothMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Ines SchumacherMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Philip BanerjeeDepartment of Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Frimley, UK.
Martin ZinkernagelDepartment of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland.
David G CharterisMoorfields Eye Hospital NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Proliferative vitreoretinopathy (PVR) is the leading cause of surgical failure in rhegmatogenous retinal detachment (RRD) and is associated with poor visual prognosis. We aimed to report changes in VFQ-25 and SF-36 tests following surgery for PVR-RRD and identify clinical and demographic factors associated with recovery.

methodsThis is a post hoc analysis of a phase IIIb randomized, participant-masked clinical trial evaluating slow-release dexamethasone in PVR-RRD. Patients underwent pars plana vitrectomy with silicone oil tamponade. Vision-related QOL was assessed using VFQ-25, and SF-36 test, at baseline, 6 months, and 12 months postoperatively. VFQ-25 subscales and SF-36 domains were analysed descriptively and with nonparametric paired tests; associations with best-corrected visual acuity (BCVA, logMAR) and other variables were assessed using Spearman correlation and nonparametric tests.

resultsA total of 139 patients were included (mean age 61 years; 60% male). VFQ-25 total score improved from a median of 65.5 at baseline to 70 at 12 months (p = 0.0004). SF-36 total score improved from 68 to 77.5 at 12 months (p = 0.006). Worse 12-month BCVA correlated with lower VFQ-25 (p < 0.001) and showed a borderline association with SF-36 (p = 0.054). In univariable analyses, women reported lower 12-month QOL; however, gender associations were attenuated in multivariable models (VFQ-25: β = -4.39, p = 0.073; SF-36: β = -4.71, p = 0.199). Retinal anatomical status and number of surgeries were not associated with QOL outcomes. Subscale/domain analyses showed the largest improvements in psychosocial domains: VFQ-25 mental health increased from 50.0 to 68.8 (p = 3.35 × 10-5), and SF-36 mental health increased from 68.0 to 80.0 (p = 2.38 × 10-6), while most physical health domains were stable.

conclusionsDespite the complexity of PVR-RRD, significant improvements in both visual function and general QOL were observed postoperatively driven largely by psychosocial recovery. Final BCVA and baseline QOL had a greater influence on perceived recovery than anatomical success or number of surgeries. These findings highlight the importance of personalized care and rehabilitation in managing PVR-RRD patients. </p>.

Indexed as

DexamethasoneEndotamponadePatient Reported Outcome MeasuresQuality of LifeVisual AcuityVitrectomyVitreoretinopathy, ProliferativeAgedDouble-Blind MethodFemaleFollow-Up StudiesGlucocorticoidsHumansMaleMiddle AgedRetinal DetachmentDexamethasoneGlucocorticoidsSilicone OilsPatient-reported outcomesProliferative vitreoretinopathyQuality of lifeRetinal detachmentRhegmatogenous retinal detachmentVitrectomy

Identifiers

PMID41610080
PMCPMC12981897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.